P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS

Bibliographic Details
Main Authors:	Jan Bewersdorf, Rory M. Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan Madanat, Joshua Zeidner, Jessica Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai Podoltsev, Stephanie Halene, Richard Little, Richard Pierkarz, Steven Gore, Tae Kon Kim, Amer M. Zeidan
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000969884.30347.e2

Similar Items

Are We Moving the Needle for Patients with <i>TP53</i>-Mutated Acute Myeloid Leukemia?
by: Rory M. Shallis, et al.
Published: (2022-05-01)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
by: Narendra Bharathy, et al.
Published: (2019-05-01)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
by: Hussein Awada, et al.
Published: (2023-04-01)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
by: Angelica Ferro, et al.
Published: (2023-02-01)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
by: Jan Philipp Bewersdorf, et al.
Published: (2019-01-01)

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
by: Rory M. Shallis, et al.
Published: (2021-11-01)

The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia
by: Rory M. Shallis, et al.
Published: (2021-12-01)

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
by: Talha Badar, et al.
Published: (2024-02-01)

A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer
by: Trish Millard, et al.
Published: (2024-01-01)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
by: Lars Ny, et al.
Published: (2021-08-01)

Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure
by: Johanna K. Freundt, et al.
Published: (2019-03-01)

Entinostat reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827 cells.
by: Takumi Tomono, et al.
Published: (2018-01-01)

MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
by: Matteo Cassandri, et al.
Published: (2021-10-01)

Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis
by: Simin Kiany, et al.
Published: (2017-08-01)

"Faint Hope" in the Firing Line: Repeal of Section 745.6?
by: Roberts, J
Published: (2009)

Cyberbezpieczeństwo wyrobów medycznych w Ğwietle rozporządzenia 2017/745
by: Jarosław Greser
Published: (2020-02-01)

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1
by: Chenyin Wang, et al.
Published: (2020-02-01)

الاقتباس والتضمين في شعر أبي حيّان الأندلسي(745هـ)
by: عمر ثامر, et al.
Published: (2023-06-01)

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
by: Kristin C. Hicks, et al.
Published: (2021-08-01)

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
by: Li Shen, et al.
Published: (2012-01-01)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
by: Norikazu Masuda, et al.
Published: (2021-11-01)

Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer
by: Maki Tanioka, et al.
Published: (2018-11-01)

Genetic testing for haemochromatosis in patients with chondrocalcinosis (vol 61, pg 745, 2002)
by: Timms, A, et al.
Published: (2003)

P745: ASSESSMENT OF MIRNA BIOGENESIS GENES VARIANTS IN MDS DEVELOPMENT AND PROGRESSION
by: D. Bug, et al.
Published: (2022-06-01)

21W.745 / WGS.576 Advanced Essay Workshop, Spring 2008
by: Faery, Rebecca Blevins
Published: (2022)

Influence of Saccharomyces boulardii CNCM I-745 on the gut-associated immune system
by: Stier H, et al.
Published: (2016-09-01)

Conditionally essential genes for survival during starvation in Enterococcus faecium E745
by: Vincent de Maat, et al.
Published: (2020-08-01)

Immunomodulation of HDAC Inhibitor Entinostat Potentiates the Anticancer Effects of Radiation and PD-1 Blockade in the Murine Lewis Lung Carcinoma Model
by: Yeeun Kim, et al.
Published: (2022-12-01)

Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat.
by: Nadja Blagitko-Dorfs, et al.
Published: (2013-01-01)

Entinostat Improves Motor Function and Neuronal Damage Via Downregulating NLRP3 Inflammasome Activation After Spinal Cord Injury
by: Chen Dai, et al.
Published: (2021-11-01)

The Link Between Hyperhomocysteinemia and Hypomethylation
by: Madalena Barroso PhD, et al.
Published: (2017-04-01)

CNCM I-745 Improves Intestinal Enzyme Function: A Trophic Effects Review
by: Margret I Moré, et al.
Published: (2018-02-01)

Saccharomyces boulardii CNCM I-745 supplementation during and after antibiotic treatment positively influences the bacterial gut microbiota
by: Madeleine Spatz, et al.
Published: (2023-08-01)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
by: Srdan Verstovsek, et al.
Published: (2016-12-01)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
by: A. Zeidan, et al.
Published: (2022-06-01)

Specific targeting of inflammatory osteoclastogenesis by the probiotic yeast S. boulardii CNCM I-745 reduces bone loss in osteoporosis
by: Maria-Bernadette Madel, et al.
Published: (2023-02-01)

New Antibacterial Bagremycins F and G from the Marine-Derived Streptomyces sp. ZZ745
by: Di Zhang, et al.
Published: (2018-09-01)

The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models
by: Young-Suk Kim, et al.
Published: (2019-07-01)

Experimental and Numerical Validation of the Improved Vortex Method Applied to CP745 Marine Propeller Model
by: Król Przemysław, et al.
Published: (2018-06-01)

Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.
by: Paola Brun, et al.
Published: (2017-01-01)